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Introduction: We report for the first time the case of a patient with Albright hereditary osteodystrophy and
pseudopseudohypoparathyroidism who underwent a Roux-en-Y gastric bypass.
Case presentation: A 26-year-old obese Caucasian woman with Albright hereditary osteodystrophy with
pseudopseudohypoparathyroidism (heterozygous mutation (L272F) in GNAS1 exon 10 on molecular analysis) was
treated with gastric bypass. She had the classical features of Albright hereditary osteodystrophy: short stature
(138cm), obesity (body mass index 49.5kg/m2), bilateral shortening of the fourth and fifth metacarpals, short neck,
round and wide face with bombed front and small eyes. Before the gastric bypass was performed, biochemical
determination revealed a slightly low serum calcium level (2.09mmol/L; normal range 2.1 to 2.5mmol/l), and an
elevated parathyroid hormone level (87ng/L; normal range 10 to 70ng/L) associated with low vitamin D level
(19μg/L; normal range 30 to 50μg/L). Vitamin D supplementation was prescribed before surgery. After the Roux-en-Y
gastric bypass, she achieved a progressive substantial weight loss, from 94kg (body mass index 49.5kg/m2) to
49kg (body mass index 25.9kg/m2) in one year. Her weight then stabilized at 50kg (body mass index 26kg/m2)
during our three years of follow-up. Before the operation and every three months after it, she was screened for
nutritional deficiencies, and serum markers of bone turnover and renal function were monitored. Considering the
deficiencies in zinc, magnesium, calcium, vitamin D and vitamin B12, appropriate supplementation was prescribed.
Before and two years after the Roux-en-Y gastric bypass, a dual-energy X-ray absorptiometry assessment of bone
density was performed that showed no changes on her lumbar column (0.882g/cm2 and both T-score and Z-score
of −1.5 standard deviation). In addition, bone microarchitecture with a measurement of her trabecular bone score
was found to be normal.
Conclusion: This is the first case of Roux-en-Y gastric bypass described in a patient with pseudopseudohypo-
parathyroidism showing that such a procedure seems to be safe in obese patients with Albright hereditary
osteodystrophy and pseudopseudohypoparathyroidism if appropriately followed up. As obesity is a prominent
feature of Albright hereditary osteodystrophy, such patients might seek bariatric surgery. After a Roux-en-Y gastric
bypass, patients with Albright hereditary osteodystrophy associated with pseudopseudohypoparathyroidism need
long-term follow-up on nutritional and metabolic issues.
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Figure 1 Hands of the patient. (A) right hand. (B) left hand.
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Albright hereditary osteodystrophy is a disorder caused by
heterozygous inactivating mutations in GNAS, the gene
encoding the alpha chain of the stimulatory G protein and
is associated with short stature, obesity, brachydactyly,
subcutaneous ossifications, dental abnormalities and cog-
nitive impairment. Because GNAS is paternally imprinted
(silenced) in certain hormone target tissues, patients with
Albright hereditary osteodystrophy with GNAS mutations
on maternally inherited alleles often manifest resistance
to multiple stimulatory G protein-coupled hormones
(for example, parathyroid hormone (PTH), thyroid-
stimulating hormone (TSH), luteinizing hormone (LH),
follicular-stimulating hormone (FSH), and/or growth
hormone-releasing hormone (GHRH)), a variant termed
pseudohypoparathyroidism type 1a. The patients who
inherit mutations on the paternal allele have the Albright
hereditary osteodystrophy developmental defects and
phenotype alone without hormonal resistance, a variant
termed pseusopseudohypoparathyroidism [1]. The severity
of Albright hereditary osteodystrophy phenotype is ex-
tremely variable, even among members of the same family
and generation [2]. Classically, the Albright hereditary
osteodystrophy obesity phenotype has been viewed as part
of both conditions since first described by Fuller Albright
in the mid-1950s [3]. Bariatric surgery still remains the
most effective treatment for morbid obesity, leading
to a reduction of comorbidities in the long term [4].
Roux-en-Y gastric bypass is one of the most frequently
performed procedures in the United States and Europe. A
small gastric pouch is formed, the jejunum is divided at
the midsection, and the distal portion of the small intes-
tine is anastomosed to the pouch, thus allowing nutrients
to bypass the duodenum and proximal jejunum. Because
these are the preferred sites for the absorption of calcium
[5], patients frequently suffer from calcium and vitamin D
deficiencies after Roux-en-Y-gastric bypass, which might
cause secondary hyperparathyroidism [6]. Long-lasting
secondary hyperparathyroidism is believed to be an
important contributing factor for increased bone turnover,
consequent bone loss and increased risk of osteoporotic
fractures. It has been known for more than 50 years that
osteomalacia and osteoporosis are frequent complications
of gastric surgery and small bowel malabsorptive disorders
[7]. Significant increase in serum markers of bone turn-
over has been documented in patients with reduced bone
density after bariatric surgery [8].
We describe, for the first time, a three-year follow-up of
Roux-en-Y gastric bypass in a patient with Albright heredi-
tary osteodystrophy and pseudopseudohypoparathyroidism.
Case presentation
This case concerns a 26-year-old Caucasian woman,
known to have Albright hereditary osteodystrophy withpseudopseudohypoparathyroidism who presented herself
to our department for treatment of her obesity. Her mo-
lecular analysis showed heterozygous mutation (L272F)
in GNAS1 exon 10. She had a previous history of con-
genital hip dysplasia, interventricular communication,
strabismus, delayed growth, renal failure stage 3 and
type 2 diabetes. She had never had a fracture.
A physical examination showed a weight of 77.7kg
with a stature of 138cm (body mass index (BMI)
40.8kg/m2). She had the classical features of Albright
hereditary osteodystrophy: short stature, obesity, short
neck, round and wide face with bombed front and small
eyes. An examination of her hands revealed a bilateral
shortening of the fourth and fifth metacarpals (Figure 1).
Biochemical determination revealed normal levels of
pituitary hormones TSH, human growth hormone
(HGH) and insulin-like growth factor 1 (IGF-1). As she
had regular menses and no signs nor symptoms of corti-
sol deficiency, we did not measure adrenocorticotropic
hormone (ACTH), FSH and LH. She had mild hypocal-
cemia (2.09mmol/L; normal range 2.1 to 2.5mmol/L),
low vitamin D level (19μg/L; normal range 30 to
50μg/L), and elevated PTH level (87ng/L; normal range
10 to 70ng/L), which was probably secondary to vitamin
D deficiency. Phosphate and magnesium were in the
normal range. Her karyotype was 46 XX.
Dual-energy X-ray absorptiometry (DEXA) assessment
of bone density showed osteopenia: 0.812g/cm2 and both
T-score and Z-score of −1.4 standard deviation (SD) on her
lumbar column L1-L4. Proximal femur bone density was
measured at 0.854g/cm2 and T-score and Z-score were
both at −0.7 SD. Beta-CrossLaps were high at 869 ng/L
(normal range: 25 to 573ng/L), signaling an increase in
bone turnover [9]. We assessed the bone microarchitecture
with a measurement of her trabecular bone score (TBS),
which is a novel gray-level texture measurement that can
be extracted from DEXA images and correlates with three-
dimensional parameters of bone microarchitecture [10].
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degraded skeletal microarchitecture (TBS of 1.189).
As she had hypovitaminosis D with osteopenia, vita-
min D was prescribed.
As far as her obesity is concerned, her eating disorder
was treated first, using group and individual psycho-
logical support, as well as dietetic and medical consulta-
tions. After two and a half years of therapy, our patient
managed to improve her eating behavior and lifestyle.
After a progressive weight gain, she could finally
stabilize her weight at 92Kg (BMI 49.5Kg/m2). She was
therefore ready to undergo a Roux-en-Y-gastric bypass.
During the first year after the procedure, she gradually
achieved a substantial weight loss: from 94kg (BMI
49.5kg/m2) to 49kg (BMI 25.9kg/m2). Afterwards, her
weight stabilized at 50kg (BMI 26kg/m2) during our
three-year follow-up. Every three months after the
Roux-en-Y gastric bypass, a screening for nutritional
deficiency was performed, as well as a measurement of
markers of renal function and bone turnover, as shown
in Table 1. Considering the deficiencies in zinc,
magnesium, calcium, vitamin D and vitamin B12, intra-
muscular vitamin B12 supplementation and oral zinc,
magnesium, calcium and D vitamin were introduced.
The doses were adjusted every three months, according
to the serum vitamin level.
Two years after the Roux-en-Y gastric bypass, a DEXA
assessment of bone density was performed, which showed
no changes on her lumbar column (0.882g/cm2 and both
T-score and Z-score of −1.5 SD), significant bone loss on
her proximal femur (from 0.854g/cm2 to 0.754g/cm2 and
a reduction of both T-score and Z-score from −0.7 SD to
−1.5 SD). This apparent bone loss on the proximal femur
is an artifact due to the significant weight loss of the
patient, and consequent fat estimation error due to vari-
ation in soft tissue hydratation [9]. We assessed the bone
microarchitecture with a measurement of TBS, which
showed normal bone microarchitecture on her lumbar
column (TBS of 1.373). It is interesting to notice a
substantial improvement in her TBS, which showed a
degraded skeletal microarchitecture in the pre-operative
measurement and normal bone microarchitecture two
years after the Roux-en-Y gastric bypass, which is partially
due to the weight loss. In the analysis of TBS, obesity often
leads to underestimation of the TBS score. The level
of Beta-CrossLaps remained high at 682ng/L (normalTable 1 Blood test results before and after gastric bypass
Months after the gastric bypass Pre-operative 3
Normal range
Parathyroid hormone 10 - 70 ng/L 96 150
25-OH vitamin D3 8.4 - 52.3 μg/L 28.1 21.1
Beta-CrossLaps 25 - 573 ng/L 869 729range: 25 to 573ng/L), slightly lower than in the pre-
operative assessment.
Discussion
This is the first case of Roux-en-Y gastric bypass
described in an obese patient with Albright hereditary
osteodystrophy and pseudopseudohypoparathyroidism.
Observations during the three-year follow-up shows that
bariatric surgery seems to be safe in such patients. As
obesity is a prominent feature of Albright hereditary
osteodystrophy [3], these patients are prone to seek
bariatric surgery. After a Roux-en-Y gastric bypass, such
patients need long-term follow-up on nutritional and
metabolic issues, as does every other patient undergoing
the same surgery [11,12]. Our patient needed calcium and
vitamin D supplementation before and after the surgery.
A comparison in the DEXA assessments of bone density
before and two years after the Roux-en-Y gastric bypass
showed no changes on her lumbar column.
Bone abnormalities of Albright hereditary osteodystrophy
and pseudopseudohypoparathyroidism are not well known
[13,14] as calcium metabolism and skeletal health after
bariatric surgery are not well known [6,15]. In our case, the
elevation of PTH before and after surgery was identical, as
well as the beta-crosslabs level. Further long-term prospect-
ive studies are critical to confirm if bariatric surgery in
obese patients with Albright hereditary osteodystrophy and
pseudopseudohypoparathyroidism is indeed safe.
Conclusion
We present the first published case of Roux-en-Y gastric
bypass in a patient with pseudopseudohypoparathyroidism
showing that such a procedure seems to be safe in
obese patients with Albright hereditary osteodystrophy
and pseudopseudohypoparathyroidism if appropriately
followed up. Obesity is a prominent feature of Albright
hereditary osteodystrophy, and such patients may seek
bariatric surgery. After a Roux-en-Y gastric bypass, patients
with Albright hereditary osteodystrophy associated with
pseudopseudohypoparathyroidism need long-term follow-
up for nutritional and metabolic issues.
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